	US 10,376,500 B2
	Gel containing pirfenidone
José Agustin Rogelio Magaña Castro, Mexico City (MX); Laura Vázquez Cervantes, Mexico City (MX); and Juan Socorro Armendáriz Borunda, Mexico City (MX)
Assigned to CELL THERAPY AND TECHNOLOGY S.A. DE C.V., Mexico City (MX)
Filed by CELL THERAPY AND TECHNOLOGY S.A. DE C.V., Mexico City (MX)
Filed on Feb. 17, 2017, as Appl. No. 15/435,494.
Application 15/435,494 is a division of application No. 13/893,626, filed on May 14, 2013, abandoned.
Application 13/893,626 is a division of application No. 12/673,304, granted, now 8,492,412, previously published as PCT/MX2008/000107, filed on Aug. 14, 2008.
Claims priority of application No. MX/a/2007/009796 (MX), filed on Aug. 14, 2007.
Prior Publication US 2017/0216268 A1, Aug. 3, 2017
Int. Cl. A01N 43/00 (2006.01); A01N 43/46 (2006.01); A61K 31/55 (2006.01); A61K 31/4418 (2006.01); A61K 9/00 (2006.01); A61K 9/06 (2006.01); A61K 47/02 (2006.01); A61K 47/18 (2017.01); A61K 47/22 (2006.01); A61K 47/32 (2006.01)

CPC A61K 31/4418 (2013.01) [A61K 9/0014 (2013.01); A61K 9/06 (2013.01); A61K 47/02 (2013.01); A61K 47/18 (2013.01); A61K 47/22 (2013.01); A61K 47/32 (2013.01)]

5 Claims

1. A method for treating fibrotic lesions in a patient in need thereof, the method comprising cutaneous administration to the patient of a Pirfenidone gel consisting of 8% Pirfenidone, 0.5% of a viscous agent, 20% of a solubilizer, 11.5% of a non ionic solubilizer, 0.5% of a conserving agent, 0.5% of a neutralizer agent and 59% of purified water, thereby treating the fibrotic lesions in the patient.